Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2019.09.09
Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submissio ...
PDF (261 KB)
2019.08.21
Updated Clinical Results and New Translational Research Data for Daiichi Sankyo’s ADCs U3-1402 and ...
PDF (297 KB)
2019.11.04
Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugat ...
PDF (132 KB)
2020.05.11
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric ...
PDF (179 KB)
2020.05.21
ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
PDF (186 KB)
2019.08.02
FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGC ...
PDF (368 KB)
2019.09.10
Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at ...
PDF (188 KB)
2019.10.17
[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with ...
PDF (171 KB)
2019.08.12
Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions
PDF (151 KB)
2020.01.06
ENHERTU® Now Available in U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following ...
PDF (253 KB)
Showing 1 - 10 of 35 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...